• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cancer cachexia: an orphan with a future.

作者信息

Lainscak Mitja, Rosano Giuseppe M C

机构信息

Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia.

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

出版信息

J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):3-5. doi: 10.1002/jcsm.12401.

DOI:10.1002/jcsm.12401
PMID:30920780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6438338/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad3/6438338/8df7bbbdd4c0/JCSM-10-3-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad3/6438338/a35f01c47641/JCSM-10-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad3/6438338/8df7bbbdd4c0/JCSM-10-3-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad3/6438338/a35f01c47641/JCSM-10-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad3/6438338/8df7bbbdd4c0/JCSM-10-3-g002.jpg

相似文献

1
Cancer cachexia: an orphan with a future.癌症恶病质：一个拥有未来的罕见病。
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):3-5. doi: 10.1002/jcsm.12401.
2
Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.在美国和欧盟中癌症恶病质的孤儿病地位：系统评价。
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):22-34. doi: 10.1002/jcsm.12402.
3
[The legal regulation of life cycle of orphan pharmaceuticals].[孤儿药生命周期的法律监管]
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2014 May-Jun(3):37-42.
4
A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.中、美、欧、日均出台孤儿药政策，如何走出中国式孤儿药之路：跨国比较研究
J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.
5
Orphan Medicines for Pediatric Use: A Focus on the European Union.儿科孤儿药：以欧盟为例。
Clin Ther. 2019 Dec;41(12):2630-2642. doi: 10.1016/j.clinthera.2019.10.006. Epub 2019 Nov 5.
6
[Orphan drugs--medications for patients with rare diseases].[孤儿药——用于罕见病患者的药物]
Ugeskr Laeger. 2006 Jun 5;168(23):2236-8.
7
Navigating through orphan medicinal product regulations in EU and US--similarities and differences.解读欧盟和美国的罕见病药品法规——异同之处
Regul Toxicol Pharmacol. 2015 Feb;71(1):63-7. doi: 10.1016/j.yrtph.2014.11.006. Epub 2014 Dec 8.
8
Does orphan drug legislation really answer the needs of patients?孤儿药立法真的能满足患者的需求吗？
Lancet. 2008 Jun 14;371(9629):2041-4. doi: 10.1016/S0140-6736(08)60873-9.
9
Drugs for rare disorders.用于罕见疾病的药物。
Br J Clin Pharmacol. 2017 Aug;83(8):1607-1613. doi: 10.1111/bcp.13331. Epub 2017 Jun 27.
10
[Hope for patients with rare diseases--"orphan" drugs].[罕见病患者的希望——“孤儿”药]
Cas Lek Cesk. 2006;145(4):296-300.

引用本文的文献

1
Nurses' Knowledge in Relation to the Anorexia-Cachexia Syndrome in Cancer Patients: A Cross-National Comparison in Two European Countries.护士对癌症患者厌食-恶病质综合征的认知：两个欧洲国家的跨国比较
SAGE Open Nurs. 2021 Sep 30;7:23779608211035208. doi: 10.1177/23779608211035208. eCollection 2021 Jan-Dec.
2
Advanced cancer is also a heart failure syndrome: a hypothesis.晚期癌症也是心力衰竭综合征：一种假说。
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):533-537. doi: 10.1002/jcsm.12694. Epub 2021 Mar 18.
3
Corrigendum.

本文引用的文献

1
Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.在美国和欧盟中癌症恶病质的孤儿病地位：系统评价。
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):22-34. doi: 10.1002/jcsm.12402.
2
Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.电子健康记录中的大数据在心血管转化研究中的早期和晚期应用：挑战与潜力。
Eur Heart J. 2018 Apr 21;39(16):1481-1495. doi: 10.1093/eurheartj/ehx487.
3
Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017.
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):1158. doi: 10.1002/jcsm.12605.
4
Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel.虚假电子医疗时代的患者及家庭支持：来自一个国际共识小组的思考素材
ESMO Open. 2020 Apr;5(2). doi: 10.1136/esmoopen-2020-000696.
《恶病质、肌肉减少症与肌肉杂志》发表伦理准则：2017 年更新版
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083. doi: 10.1002/jcsm.12261. Epub 2017 Nov 3.
4
'Big data' approaches for novel anti-cancer drug discovery.用于新型抗癌药物发现的“大数据”方法。
Expert Opin Drug Discov. 2017 Jun;12(6):599-609. doi: 10.1080/17460441.2017.1319356. Epub 2017 May 2.
5
Welcome to the ICD-10 code for sarcopenia.欢迎使用 ICD-10 代码来诊断肌少症。
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):512-514. doi: 10.1002/jcsm.12147. Epub 2016 Oct 17.
6
Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016.欧洲、美国和日本慢性疾病恶病质的流行情况及其对临床的影响：2016 年的事实和数据更新。
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509. doi: 10.1002/jcsm.12167. Epub 2016 Nov 2.
7
ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.第一幕——通过采用一种新型β受体阻滞剂，终于对癌症恶病质采取行动了。
J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):400-2. doi: 10.1002/jcsm.12136. Epub 2016 Aug 5.
8
National trends in heart failure hospitalization rates in Slovenia 2004-2012.斯洛文尼亚 2004-2012 年心力衰竭住院率的国家趋势。
Eur J Heart Fail. 2016 Nov;18(11):1321-1328. doi: 10.1002/ejhf.617. Epub 2016 Sep 9.
9
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).埃斯平多洛用于治疗和预防 III/IV 期非小细胞肺癌或结直肠癌患者恶病质：一项随机、双盲、安慰剂对照的国际多中心 II 期研究（ACT-ONE 试验）。
J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):355-65. doi: 10.1002/jcsm.12126. Epub 2016 Jul 1.
10
Heart failure epidemiology 2000-2013: insights from the German Federal Health Monitoring System.心力衰竭流行病学 2000-2013：来自德国联邦健康监测系统的见解。
Eur J Heart Fail. 2016 Aug;18(8):1009-18. doi: 10.1002/ejhf.567. Epub 2016 Jun 1.